方法：本研究共纳入46例46眼糖尿病性白内障患者，均为非增殖期糖尿病性视网膜病变，不合并明显的黄斑水肿。随机分为2组，对照组单纯行白内障超声乳化摘除，研究组除行白内障超声乳化摘除外合并玻璃体内注射雷珠单抗； 观察的指标包括最佳矫正视力、眼压、黄斑区视网膜厚度及并发症的情况； 观察时间分别为术前、术后1，6mo。

结果：两组患者术前和术后1mo最佳矫正视力及黄斑区下视网膜厚度无差异； 术后6mo时研究组最佳矫正视力优于对照组，黄斑区下视网膜厚度薄于对照组(P<0.05)； 术后6mo时，研究组黄斑水肿(黄斑区下视网膜厚度比对照组>60μm)出现的比率为13.0%，显著低于对照组(47.8%，P=0.033)； 两组患者并发症无明显差异，均未见到严重并发症。

结论：雷珠单抗玻璃体腔注射可以减低糖尿病性白内障术后黄斑水肿的发展，提高术后最佳矫正视力。

METHODS: Forty-six patients(46 eyes)were recruited in this study. All of the patients were non-proliferative diabetic retinopathy without significant macular edema. They were randomly divided into two groups, the control group simply performed phacoemulsification, while the study group performed intravitreal Ranibizumab injection and phacoemulsification. Observation of indicators included the condition of best corrected visual acuity(BCVA), intraocular pressure, macular retinal thickness and complication at preoperative and postoperative 1, 6mo.

RESULTS:BCVA and macular retinal thickness of patients in two groups had no differences in the preoperative and postoperative 1mo. At postoperative 6mo, the BCVA of the study group was better than that in the control group, while its macular retinal thickness was thinner than that in the control group(P<0.05). The ratio of macular edema(central macular thickness was >60μm than that in control group)was 13.0% eyes in the study group which was significantly lower than the control group(47.8%; P=0.033). The complications was no significant differences in two groups and neither occurred severe complications.

CONCLUSION:Intravitreal Ranibizumab injection can reduce the development of macular edema and improve the BCVA after phacoemulsification.